Organ damage progression in antiphospholipid antibody carriers: a longitudinal cohort study
Authors: Cantera Estefania, Rodrigo; Galvez Sanchez, Rafael; Oviedo Madrid, Maria; Abando Casuso, Maria; Cruz Barquin, Hector; Garcia Ruiz, Raquel; Herrero Lopez, Marina; Flores Garcia, Jose Antonio; Gorostidi Alvarez, Irene; Gabrie Rodriguez, Ligia Gabriela; Yanez San Segundo, Lucrecia; Lopez Hoyos, Marcos; Dominguez-Garcia, Juan Jose; Gonzalez Ponte, Maria Luisa; Gonzalez-Mesones Galan, Belen; Hernandez Hernandez, Jose Luis; Martinez Taboada, Victor Manuel
Source journal: Arthritis research & therapy (2026-08-06)
DOI: 10.1186/s13075-026-03879-7
Abstract
BACKGROUND: The DIAPS scale is a useful tool for quantifying organ damage in antiphospholipid syndrome (APS). However, little is known about the kinetics of organ damage in antiphospholipid antibody (aPL) carriers. This study aimed to characterize damage progression in aPL carriers, assess the impact of 2023 ACR/EULAR laboratory domains, autoimmune disease, and thromboprophylaxis on this progression, and determine whether organ damage at diagnosis is associated with the later development of clinical manifestations. METHODS: A retrospective observational study was conducted, including patients who met the 2023 ACR/EULAR domains 7 or 8 without clinical symptoms between January 2018 and March 2024. A total of 985 patients were analysed. RESULTS: The overall mean DIAPS score was slightly higher in patients with persistent LA compared with those without (0.429 [IQR 0.134-0.723] vs. 0.350 [IQR 0.132-0.569]). The time*autoimmune disease interaction was significant (F = 4.532, p = 0.000), indicating a steeper increase in DIAPS among patients with associated autoimmune disease. Primary thromboprophylaxis with antiplatelet agents did not modify DIAPS progression (F = 1.357, p = 0.220). Finally, organ damage at the time of serological diagnosis was associated with a higher likelihood of progression to clinical APS. CONCLUSIONS: Among aPL carriers, persistent LA positivity emerged as the most robust serological predictor of organ damage accrual. Accumulated organ damage appears to progress more rapidly in aPL carriers with an associated autoimmune disease. Organ damage at diagnosis was associated with an increased likelihood of progressing to clinical APS.
Related topics
Related open access articles
- Effect of pyrolysis temperature on ochratoxin A adsorption mechanisms and kinetics by cashew nut shell biochars
- Drying characteristics and solar convective drying kinetics of China Hami melon slice
- Kinetic study of photocatalytic degradation of Ifos famide in a microchannel and simulation
- Photocatalytic degradation of microcystin-LR by modified high-energy {001} titanium dioxide: Kinetics and mechanism study of HF8
- Yoghurt powder production using microwave–vacuum drier: drying kinetics, mathematical modeling, and characteristics
- Adsorptive and kinetic characterization of aqueous zinc removal by biochars
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.